Cue Biopharma, Inc.
CUE
$0.84
$0.02182.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.61% | 0.73% | 29.31% | 21.31% | 22.86% |
| Total Depreciation and Amortization | -2.17% | 2.02% | -31.47% | -9.80% | 3.87% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -50.39% | -21.18% | -671.07% | -10.13% | -19.72% |
| Change in Net Operating Assets | 219.69% | 765.69% | -39.26% | -617.07% | -6,095.00% |
| Cash from Operations | 65.82% | 16.48% | 17.61% | 3.49% | 3.67% |
| Capital Expenditure | -170.00% | -172.73% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -170.00% | -172.73% | -- | -98.04% | -100.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.10% | 0.00% | -- |
| Issuance of Common Stock | -- | -- | -98.84% | 93.61% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,879.80% | -142.48% | -119.49% | 114.01% | -147.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 230.51% | -24.54% | -61.29% | 33.63% | -236.39% |